Formulary guidance and transparency from P&T to point of care


Reality Check on Endometriosis

Market access for endometriosis treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.  

To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:

  • Payer Insights: Under the pharmacy benefit, about 53% of the lives under commercial formularies are covered with utilization management restrictions
  • Class Trends: In April 2020, Myovant Sciences reported positive results in its Phase III studies of once-daily relugolix combination therapy for pain associated with endometriosis
  • Key Findings: Minimal contracting is seen for this indication. With Lupaneta Pack (leuprolide acetate for depot suspension and norethindrone acetate tablets), Lupron Depot (leuprolide acetate for depot suspension) and the approval of Orilissa, AbbVie continues to have a strong presence in the endometriosis market

What can pharma do to curb this trend and overcome these challenges?

Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.

Download the full Reality Check now.